Clinical Trials Directory

Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH

FSGS is an immunologic disorder wherein circulating immune proteins cause damage to the kidneys and progressive injury and scarring. Corticosteroid therapy is occasionally, but not nearly universally, successful in reducing proteinuria, and when patients respond, they have a favorable prognosis. The investigators believe that ACTH therapy (H.P. Acthar Gel) can provide a more rapid, well tolerated reduction in glomerular injury.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : H.P. Acthar Gel

Phase: Phase 4


Ages Eligible For Study:

16 Years - 65 Years

Inclusion Criteria

- 1. Biopsy proven FSGS - 2. Ability to consent and complete study evaluations - 3. Greater than 2g/day of proteinuria - 4. No contraindications to treatment with corticosteroids or ACTH - 5. Women of childbearing potential will agree to use effective forms of birth control throughout this study

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Richard Lafayette
(650) 723-6248
Not Recruiting

Footer Links: